Ligand Pharmaceuticals LGND Accrued royalty from financial royalty assets
Accrued royalty from financial royalty assets at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid.
The official record: Ligand Pharmaceuticals’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's accrued royalty from financial royalty assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's accrued royalty from financial royalty assets?
- Ligand Pharmaceuticals (LGND) reported accrued royalty from financial royalty assets of $0 in Q4 2025.
- What does accrued royalty from financial royalty assets mean?
- Represents royalty revenue earned from commercial partners that has been recognized in the financial statements but not yet collected in cash. This metric tracks the lag between the performance of licensed products and the actual receipt of royalty payments. It is a critical indicator of the company's working capital efficiency regarding its intellectual property monetization.